TITLE:
Clinical Characteristics and Risk Factors of Dyslipidemia in AIDS Patients Treated with ART
AUTHORS:
Da Huang, Huiquan Lu, Caihua Zou, Ye Liang, Jindu Li, Tianzi Li
KEYWORDS:
AIDS, Antiviral Therapy, Dyslipidemia, Clinical Characteristics, Risk Factors
JOURNAL NAME:
World Journal of Cardiovascular Diseases,
Vol.16 No.10,
October
20,
2026
ABSTRACT: Background: The incidence of dyslipidemia in patients with AIDS and antiviral therapy was relatively high. Patients with AIDS and antiviral therapy with dyslipidemia have a high risk of vascular disease emergencies, which seriously threatened the life and health of patients, and the pathogenesis and drug safety of have attracted much attention. Objective: To explore the prevalence and risk factors of dyslipidemia in AIDS patients treated with antiviral therapy, so as to provide basis for improving the safety of antiviral drugs, avoiding the occurrence of vascular disease emergencies, and ensuring the long-term health of patients. Methods: Total cholesterol (TC) and triglyceride (TG) were measured in 161 patients with AIDS after antiviral therapy for 1, 2 and 3 years. TC ≥ 5.72 mmol/l or TG ≥ 2.58 mmol/l were included in the observation group, and TC +T, CD8+T, viral load (HIVL), leukocyte (WBC), hemoglobin (HB), platelet (PLT), bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood creatinine (BCR), TC, TG and blood glucose (BG) levels of the two groups were compared, and the influencing factors were calculated by Logistic regression. Results: The dyslipidemia rate of AIDS patients treated with antiviral therapy was 46.6% (75/161) for one year, 60.2% (97/161) for two years and 76.4% (123/161) for three years. The longer the course of therapy, the higher the rate of dyslipidemia (Χ2 = 30.168, P Χ2 = 4.628, P X2 = 17.087, P X2 = 12.633, P Conclusion: Patients receiving antiretroviral therapy for HIV/AIDS have a high prevalence of dyslipidemia; the prevalence is particularly high among male patients, those hypertension, and those with arteriosclerosis, and increases with the duration of treatment. For HIV/AIDS antiretroviral therapy, it is essential to actively control patients’ pressure and lipid levels, prevent the occurrence of vascular events, and ensure their long-term health.